F. Hoffmann-La Roche AG

• A Study to Evaluate Effects of Atezolizumab (anti-PD-L1 antibody) as an Adjuvant Therapy in Patients with High-Risk Muscle-invasive Bladder … Ended
  2022-502705-15-00 Phase III 9 countries ATEZOLIZUMAB
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa… Ended
  2023-506911-16-00 Phase III 11 countries GIREDESTRANT; LETROZOLE; PALBOCICLIB
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc… Ended
  2022-502611-10-00 Phase III 11 countries
• A Study of Atezolizumab with or without Tiragolumab in Participants with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have … Ended
  2022-502052-30-00 Phase III 9 countries ATEZOLIZUMAB; TIRAGOLUMAB
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc… Ended
  2023-506515-18-00 Phase III 11 countries DIPHENHYDRAMINE HYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended
  2023-506467-34-00 Phase III 10 countries DIPHENHYDRAMINE HYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in… Ended
  2023-505812-39-00 Phase III 9 countries FULVESTRANT; INAVOLISIB
• A Study Evaluating the Safety, Pharmacokinetics (what the body does to a drug), and Efficacy of Mosunetuzumab given subcutaneously (SC) or i… Ended
  2023-507236-20-00 Phase I/II 2 countries LENALIDOMIDE; MOSUNETUZUMAB; TOCILIZUMAB
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with ISN/RPS 2003 Class III or IV Lupus Nephritis Ended
  2023-503628-22-00 Phase III 5 countries MYCOPHENOLATE MOFETIL; OBINUTUZUMAB
• A study to look at how safe and effective glofitamab plus R-CHOP in ctDNA high-risk people with untreated diffuse large B-cell lymphoma Ended
  2023-504994-19-00 Phase II 5 countries GLOFITAMAB; TOCILIZUMAB
• Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have … Ended
  2023-505088-35-00 Phase I/II 4 countries ENTRECTINIB
• A Study of Atezolizumab (Anti-PD-L1 Antibody) plus Bevacizumab versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellula… Ended
  2023-504303-86-00 Phase III 9 countries ATEZOLIZUMAB; BEVACIZUMAB
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Rela… Ended
  2023-507313-94-00 Phase II 2 countries DIPHENHYDRAMINE HYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
• Dose Escalation and Dose Expansion Study of PD1-LAG3 Bispecific Antibody in Patients with Advanced and/or Metastatic Solid Tumors Ended
  2023-503425-18-00 Phase I 2 countries
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ended
  2023-505980-36-00 Phase III 9 countries DIPHENHYDRAMINE HYDROCHLORIDE; OCRELIZUMAB
• An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizu… Ended
  2023-506184-34-00 Phase III 11 countries ALECTINIB; ALECTINIB HYDROCHLORIDE; ATEZOLIZUMAB; CABOZANTINIB; COBIMETINIB; NIR…
• A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, a CD19 targeted 4-1BB l… Ended
  2022-502616-37-00 Phase I/II 5 countries ENGLUMAFUSP ALFA; GLOFITAMAB; OBINUTUZUMAB; TOCILIZUMAB
• A Study of Risdiplam in Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy Ended
  2023-506009-20-00 Phase II 2 countries RISDIPLAM
• A Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Re… Ended
  2023-506861-76-00 Phase III 10 countries ALECTINIB; CARBOPLATIN; CISPLATIN; GEMCITABINE HYDROCHLORIDE; PEMETREXED
• A Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients with Progressive Multiple Sclerosis Ended
  2023-506429-13-00 Phase III 7 countries DIPHENHYDRAMINE HYDROCHLORIDE; METHYLPREDNISOLONE; OCRELIZUMAB; PARACETAMOL
• A Study of Glofitamab (RO7082859) and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patient… Ended
  2023-505222-34-00 Phase I (FiH) 4 countries
• An Extension and Long-Term Observational Study In Patients Previously Enrolled in a Genentech− and/Or F. Hoffmann-La Roche Ltd−Sponsored Ate… Ended
  2023-506186-57-00 Phase III 6 countries ATEZOLIZUMAB
• A Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small C… Ended
  2023-507500-31-00 Phase II/III 6 countries
• A Study to Assess Safety, Effectiveness, Pharmacokinetics, and Pharmacodynamics of RO7112689 in Healthy Volunteers and Patients with Paroxys… Ended
  2023-506287-14-00 Phase I (FiH) 4 countries CROVALIMAB

Showing 121–144 of 213 trials